Skip to main content

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience

Written by Customer Service on . Posted in Public Companies.

NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout.

LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) — BioAdaptives, Inc. (OTC: BDPT), an innovator in evidence-based wellness solutions, today announced the upcoming national release of NeuroRush™, a next-generation nootropic designed to support sustained cognitive performance, mental clarity, and stress adaptability. Following strong results in targeted test markets, NeuroRush™ is scheduled for full commercial release in August/September 2025.

Developed as a premium adaptogen-based formula, NeuroRush™ combines six clinically studied ingredients—including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens—to deliver a balanced, non-jittery experience designed for high-functioning individuals. The product will be available in two formulations: one with natural caffeine for fast-acting mental energy, and a caffeine-free version for users sensitive to stimulants.

“We saw exceptional results in controlled launch markets,” said James Keener, CEO of BioAdaptives. “Customers reported not only better focus and productivity, but also a noticeable improvement in mood, stress control, and cognitive stamina. NeuroRush™ represents our commitment to delivering plant-based performance solutions grounded in science.”

NeuroRush™ is formulated to target multiple pathways involved in brain function and stress resilience, making it ideal for professionals, students, athletes, and older adults seeking enhanced mental performance without dependency or crash. The proprietary blend includes adaptogens, neurotransmitter precursors, and nootropic herbs that work synergistically to support dopamine balance, neuroplasticity, and mental endurance.

BioAdaptives plans to distribute NeuroRush™ through select online retailers, direct-to-consumer channels, and strategic health & wellness partners nationwide. Initial consumer feedback has highlighted NeuroRush™ as a high-performance solution that stands apart from conventional stimulant-based brain products.

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based natural health and wellness products for both humans and animals. Its formulations leverage cutting-edge research in stem cell biology, adaptogens, and regenerative nutrition. The company’s mission is to enhance the quality of life through innovation that works in harmony with the body’s natural processes.

For more information, visit: www.bioadaptives.com

Contact:
Emily Harrison
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com 

Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.